연구동향 분석

FOXO1 Suppression Is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells through MET Upregulation

박진주 최이슬 고영산 김영훈 표정수 장보건 김민아 이재선 장미수 박종완 이병란 2018년

논문상세정보
인용/피인용

' FOXO1 Suppression Is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells through MET Upregulation' 의 참고문헌

  • miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN
    Zhao M [2016]
  • Trastuzumab-resistant cells rely on a HER2-PI3KFoxO-survivin axis and are sensitive to PI3K inhibitors
  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Bang YJ [2010]
  • The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas
    Nakajima M [1999]
  • The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
    Goto T [2008]
  • The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
    Kim JW [2008]
  • The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway
    Park J [2014]
  • Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer
    Kim HP [2014]
  • Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
  • Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
    Spector NL [2005]
  • Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells
    Han CY [2008]
  • Oncogene addiction: setting the stage for molecularly targeted cancer therapy
    Sharma SV [2007]
  • Novel targeted agents for gastric cancer
    Liu L [2012]
  • Mechanisms of drug inhibition of signalling molecules
  • MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
    Lee HE [2012]
  • MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Engelman JA [2007]
  • MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells
    Chen CT [2012]
  • Loss of FOXO1 promotes gastric tumour growth and metastasis through upregulation of human epidermal growth factor receptor 2/neu expression
    Ko YS [2015]
  • Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study
    Satoh T [2014]
  • HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy
    Ha SY [2015]
  • HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
    Gravalos C [2008]
  • Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer
    Zhang Z [2014]
  • FOXO1A is a target for HER2-overexpressing breast tumors
    Wu Y [2010]
  • Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers: role of estrogen receptor and HER2 reactivation
    Wang YC [2011]
  • Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition
    Huang D [2016]
  • Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW57-2016) in an expanded panel of human normal and tumour cell lines
    Rusnak DW [2007]
  • Apoptosis in human fibrosarcoma cells is induced by a multimeric synthetic Tyr-Ile-Gly-Ser-Arg (YIGSR)-containing polypeptide from laminin
    Kim WH [1994]
  • Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
    Corso S [2010]